Basics CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. IPO Date: October 19, 2016 Sector: Healthcare Industry: Biotech Market Cap: $4.99B Activated in VL: True Average Daily Range Avg Daily Range: $1.61 | 2.80% Avg Daily Range (30 D): $1.22 | 2.12% Avg Daily Range (90 D): $1.18 | 2.40% Institutional Daily Volume Avg Daily Volume: 1.16M Avg Daily Volume (30 D): 2.34M Avg Daily Volume (90 D): 2.54M Trade Size Avg Trade Size (Sh.): 63 Avg Trade Size (Sh.) (30 D): 54 Avg Trade Size (Sh.) (90 D): 60 Institutional Trades Total Inst.Trades: 5,603 Avg Inst. Trade: $2.88M Avg Inst. Trade (30 D): $3.95M Avg Inst. Trade (90 D): $4.04M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $5.22M Avg Closing Trade (30 D): $10.6M Avg Closing Trade (90 D): $11.89M Avg Closing Volume: 81.61K     News Sep 4, 2025 @ 2:15 PM Why This Biotech Company Could Be a Growth Stock P... Source: Prosper Junior Bakiny Sep 2, 2025 @ 10:00 AM Gene Editing Market to Surpass USD 15.46 Billion b... Source: Sns Insider Aug 5, 2025 @ 11:15 AM Up 50% in 3 Months, Is This Stock Still a Buy? Source: Prosper Junior Bakiny Jul 28, 2025 @ 11:15 AM The 3 Things That Matter for Vertex Pharmaceutical... Source: Prosper Junior Bakiny Jul 21, 2025 @ 4:07 AM 3 Monster Stocks in the Making to Buy Right Now Source: Multiple Motley Fool Contributors Financials   TTM Q2 2025 Q1 2025 Basic EPS $-5.41 $-2.4 $-1.58 Diluted EPS $-5.41 $-2.4 $-1.58 Revenue $ 38.05M $ .89M $ .87M Gross Profit $ $ $ Net Income / Loss $ -467.8M $ -208.55M $ -136M Operating Income / Loss $ -552.47M $ -229.32M $ -148.42M Cost of Revenue $ $ $ Net Cash Flow $ -290.96M $ -41.65M $ -63.11M PE Ratio